Evaluation of pharmacogenomics and hepatic nuclear imaging-related covariates by population pharmacokinetic models of irinotecan and its metabolites.

MLA

Liu, Zheng, et al. “Evaluation of Pharmacogenomics and Hepatic Nuclear Imaging-Related Covariates by Population Pharmacokinetic Models of Irinotecan and Its Metabolites.” European Journal of Clinical Pharmacology, vol. 78, no. 1, Jan. 2022, pp. 53–64. EBSCOhost, https://doi.org/10.1007/s00228-021-03206-w.

APA

Liu, Z., Martin, J. H., Liauw, W., McLachlan, S.-A., Link, E., Matera, A., Thompson, M., Jefford, M., Hicks, R. J., Cullinane, C., Hatzimihalis, A., Campbell, I., Crowley, S., Beale, P. J., Karapetis, C. S., Price, T., Burge, M. E., & Michael, M. (2022). Evaluation of pharmacogenomics and hepatic nuclear imaging-related covariates by population pharmacokinetic models of irinotecan and its metabolites. European Journal of Clinical Pharmacology, 78(1), 53–64. https://doi.org/10.1007/s00228-021-03206-w

Chicago

Liu, Zheng, Jennifer H Martin, Winston Liauw, Sue-Anne McLachlan, Emma Link, Anetta Matera, Michael Thompson, et al. 2022. “Evaluation of Pharmacogenomics and Hepatic Nuclear Imaging-Related Covariates by Population Pharmacokinetic Models of Irinotecan and Its Metabolites.” European Journal of Clinical Pharmacology 78 (1): 53–64. doi:10.1007/s00228-021-03206-w.